Best confirmed cytogenetic and hematologic responses to dasatinib
| . | Follow-up at 6 mo . | Follow-up at 8 mo . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| n | 186 | 127 | 59 | 186 | 127 | 59 |
| Complete hematologic response, no. (%) | 168 (90) | 111 (87) | 57 (97) | 168 (90) | 111 (87) | 57 (9%) |
| Cytogenetic response, no. (%) | ||||||
| Major | 83 (45) | 40 (31) | 43 (73) | 97 (52) | 50 (39) | 47 (80) |
| Complete | 61 (33) | 28 (22) | 33 (56) | 73 (39) | 35 (28) | 38 (64) |
| Partial | 22 (12) | 12 (9) | 10 (17) | 24 (13) | 15 (12) | 9 (15) |
| Minor | 9 (5) | 8 (6) | 1 (2) | 7 (4) | 6 (5) | 1 (2) |
| Minimal | 19 (10) | 17 (13) | 2 (3) | 16 (9) | 15 (12) | 1 (2) |
| . | Follow-up at 6 mo . | Follow-up at 8 mo . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| n | 186 | 127 | 59 | 186 | 127 | 59 |
| Complete hematologic response, no. (%) | 168 (90) | 111 (87) | 57 (97) | 168 (90) | 111 (87) | 57 (9%) |
| Cytogenetic response, no. (%) | ||||||
| Major | 83 (45) | 40 (31) | 43 (73) | 97 (52) | 50 (39) | 47 (80) |
| Complete | 61 (33) | 28 (22) | 33 (56) | 73 (39) | 35 (28) | 38 (64) |
| Partial | 22 (12) | 12 (9) | 10 (17) | 24 (13) | 15 (12) | 9 (15) |
| Minor | 9 (5) | 8 (6) | 1 (2) | 7 (4) | 6 (5) | 1 (2) |
| Minimal | 19 (10) | 17 (13) | 2 (3) | 16 (9) | 15 (12) | 1 (2) |
Major cytogenetic response defined as the proportion of patients with complete or partial cytogenetic responses.